|
Originally published In Press as doi:10.1074/jbc.M202824200 on June 14, 2002
J. Biol. Chem., Vol. 277, Issue 39, 36499-36508, September 27, 2002
Mutations in the Helix 3 Region of the Androgen Receptor Abrogate
ARA70 Promotion of 17 -Estradiol-induced Androgen Receptor
Transactivation*
Tin Htwe
Thin ,
Eungseok
Kim ,
Shuyuan
Yeh ,
Erik R.
Sampson,
Yei-Tsung
Chen,
Loretta L.
Collins,
Ravi
Basavappa§, and
Chawnshang
Chang¶
From the George Whipple Laboratory for Cancer Research, Departments
of Pathology, Urology, and Radiation Oncology and the Cancer Center,
University of Rochester, Rochester, New York 14642
The influence of estrogen on the development of
the male reproductive system may be interrupted in a subset of partial
androgen insensitivity syndrome (PAIS) patients. PAIS describes a wide range of male undermasculinization resulting from mutations in the
androgen receptor (AR) or steroid metabolism enzymes that perturb
androgen-AR regulation of male sex organ development. In this study, we
are interested in determining if PAIS-derived AR mutants that respond
normally to androgen have altered responses to estrogen in the presence
of ARA70, a coregulator previously shown to enhance 17 -estradiol
E2-induced AR transactivation. The wild-type AR (wtAR) and two PAIS AR
mutants, AR(S703G) and AR(E709K), all bind to androgen and E2 and
subsequently translocate to the nucleus. Whereas ARA70 functionally
interacts with the wtAR and the PAIS AR mutants in response to
androgen, E2 only promotes the functional interaction between ARA70 and
the wtAR but not the PAIS AR mutants. ARA70 increases E2 competitive
binding to the wtAR in the presence of low level androgen and also
retards E2 dissociation from the wtAR. ARA70 is present in both the
cytoplasm and the nucleus of various mouse testicular cells during
early embryogenesis day 16, at postpartum day 0 during estradiol
synthesis and in the Leydig cells at postpartum day 49. ARA70
may be unable to modulate the PAIS AR mutants-E2 binding, diminishing
the effect of E2 via AR during male reproductive system development in
patients with such mutations. Therefore, the presence of ARA70 in the
testosterone and E2-producing Leydig cells may enhance the overall
activity of AR during critical stages of male sex organ development.
*
This work was supported by the George Whipple Professorship
Endowment and National Institutes of Health Grant DK60905, and DAMD17-01-10386.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this work.
§
Research Scholar of the Leukemia and Lymphoma Society of America.
¶
To whom correspondence should be addressed. Tel.:
585-273-4500; Fax: 585-756-4133; E-mail:
chang@URMC.rochester.edu.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Yang, Y.-J. Chang, H. Miyamoto, S. Yeh, J. L. Yao, P. A. di Sant'Agnese, M.-Y. Tsai, and C. Chang
Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54
Endocrinology,
March 1, 2007;
148(3):
1340 - 1349.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yang, Y.-J. Chang, H. Miyamoto, J. Ni, Y. Niu, Z. Chen, Y.-L. Chen, J. L. Yao, P. A. di Sant'Agnese, and C. Chang
Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth
Mol. Endocrinol.,
February 1, 2007;
21(2):
343 - 358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Hu, S. Yeh, S.-D. Yeh, E. R. Sampson, J. Huang, P. Li, C.-L. Hsu, H.-J. Ting, H.-K. Lin, L. Wang, et al.
Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer
J. Biol. Chem.,
August 6, 2004;
279(32):
33438 - 33446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev.,
April 1, 2004;
25(2):
276 - 308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. H. Thin, L. Wang, E. Kim, L. L. Collins, R. Basavappa, and C. Chang
Isolation and Characterization of Androgen Receptor Mutant, AR(M749L), with Hypersensitivity to 17-beta Estradiol Treatment
J. Biol. Chem.,
February 21, 2003;
278(9):
7699 - 7708.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|